Identified a distinct CD34+CD123+CD99+CD25+ immunophenotype that was present in ∼30–40% of FLT3-ITD AML. This population was detectable at diagnosis in some patients who later acquired FLT3-ITD relapse, suggesting it may mark high-risk subclones. The study primarily focused on genetic correlation rather than LSC phenotyping. Here, FLT3 is linked to acute myeloid leukemia.